Qualigen Therapeutics Divests FastPack® Diagnostics Business
All cash deal with Chembio Diagnostics, a US Subsidiary of the French Diagnostics Company BIOSYNEX, SA, solidifies Qualigens strategic priority…
1,280€
1,59%
Echtzeit-Aktienkurs BIOSYNEX INH. EO-,10
Bid:
Ask:
Nachrichten zur BIOSYNEX INH. EO-,10 Aktie
ProciseDx Announces Acquisition by Biosynex S.A. to Transform Biologics Therapeutic Drug Monitoring in the US
Breakthrough ProciseDx diagnostic technology enables quantitative 5-minute tests for Therapeutic Drug Monitoring SAN DIEGO, June 13, 2023 /PRNewswire/ -- ProciseDx…
Biosynex Completes Acquisition of Chembio Diagnostics, Inc.
Chembio Diagnostics, Inc. becomes the first North American structure controlled by Biosynex in North America...…
Chembio Stockholders Urged to Tender Shares Before 6:00 P.M., New York City Time, on April 26, 2023
Failure to tender shares could result in the termination of the proposed merger between Chembio and Biosynex Failure to tender…
Biosynex again extends tender offer for Chembio acquisition
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Chembio Stockholders Reminded to Tender Shares Before 6:00 P.M., New York City Time, on April 12, 2023
MEDFORD, N.Y., April 10, 2023 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company…
Biosynex Extends Tender Offer for the shares of Chembio Diagnostics, Inc.
STRASBOURG, France, March 29, 2023 (GLOBE NEWSWIRE) -- Biosynex SA (“Biosynex”) (EPA: ALBIO), a French market leader specializing…
Biosynex Extends Tender Offer for the shares of Chembio Diagnostics, Inc.
STRASBOURG, France, March 15, 2023 (GLOBE NEWSWIRE) -- Biosynex SA (“Biosynex”) (EPA: ALBIO), a French market leader specializing…
Chembio Diagnostics jumps ~26% postmarket after Biosynex to buy co in $17.2M deal
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Biosynex and Chembio Diagnostics Announce Definitive Acquisition Agreement
Complementary Technologies, Product Portfolios, and Market Opportunities Expected to Represent Significant Growth Drivers...…